Cargando…
CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma
BACKGROUND: The majority of patients with recurrent or metastasized head and neck squamous cell carcinoma (HNSCC) do not benefit from immune checkpoint blockade (ICB) while several patients experience severe and persistent immune-mediated side effects. Therefore, predictive biomarkers are urgently n...
Autores principales: | Hoffmann, Friederike, Franzen, Alina, de Vos, Luka, Wuest, Lennert, Kulcsár, Zsófi, Fietz, Simon, Maas, Alexander Philippe, Hollick, Sarah, Diop, Marie Yatou, Gabrielpillai, Jennis, Vogt, Timo, Kuster, Pia, Zarbl, Romina, Dietrich, Joern, Kristiansen, Glen, Brossart, Peter, Landsberg, Jennifer, Strieth, Sebastian, Dietrich, Dimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327338/ https://www.ncbi.nlm.nih.gov/pubmed/37415208 http://dx.doi.org/10.1186/s13148-023-01525-6 |
Ejemplares similares
-
CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)
por: Fietz, Simon, et al.
Publicado: (2020) -
Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors
por: Bao, Yilin, et al.
Publicado: (2021) -
ICOS DNA methylation regulates melanoma cell-intrinsic ICOS expression, is associated with melanoma differentiation, prognosis, and predicts response to immune checkpoint blockade
por: Ralser, Damian J., et al.
Publicado: (2023) -
Nectin-4 is widely expressed in head and neck squamous cell carcinoma
por: Sanders, Christine, et al.
Publicado: (2022) -
DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy
por: Niebel, Dennis, et al.
Publicado: (2022)